fbpx
Menstrual Cycle Study: Identifying changes in insulin sensitivity across the menstrual cycle in T1D

Menstrual Cycle Study: Identifying changes in insulin sensitivity across the menstrual cycle in T1D

by | Dec 13, 2023

Back to Projects

Menstrual Cycle Study: Identifying changes in insulin sensitivity across the menstrual cycle in T1D

DCB and Tidepool are entering a partnership to explore the relationship between diabetes and women’s health. The first initiative in this collaboration focuses on the menstrual cycle’s influence on insulin-dependent diabetes.

Menstrual Cycle Study

Recognising the challenges faced by women with insulin-dependent diabetes, research specifically investigating the menstrual cycle’s impact on diabetes management remains limited so far. This lack of focused study has hindered the development of tailored treatment strategies for women.

Diabetes Center Berne (DCB) and Tidepool aim to fill this critical research gap. The joint effort is focused on examining the interplay between the menstrual cycle and diabetes management, with the goal of enhancing care and improving quality of life.

With the goal of supporting the development of clinical guidance, tools, and products to reduce the burden of diabetes management throughout the menstrual cycle, Tidepool and DCB are joining forces to explore the relationship between menstrual cycles and insulin-dependent diabetes. While Tidepool facilitates access to the data of people living with type 1 diabetes who menstruate and provides their expertise in data collection for this initiative, DCB provides expertise in clinical research and research infrastructure.

Project team: Dr. Martina Rothenbühler (Project Leader Data Sciences, DCB), Stefanie Hossmann (Clinical Research Scientist, DCB), Maya Friedman (Founder of the Tidepool Period Project, Tidepool), Saira Khan-Gallo (Access & Equity Lead, Tidepool)

Project partner: Tidepool

 

About the Study Partners

DCB supports ideas and projects in the field of diabetes technology worldwide by providing expertise, access to clinical research facilities and its own laboratories, as well as financial resources. The goal is to bring them a big step closer to market entry in a collaborative partnership. The work of the DCB is non-profit –  the goals are new insights and innovations around diabetes management as well as a vibrant community. 

Tidepool is a 501(c)(3) nonprofit organization. It was founded by people with diabetes, caregivers, and leading healthcare providers committed to helping all people with insulin-requiring diabetes safely achieve great outcomes through more accessible, actionable, and meaningful diabetes data.

Study requirements for U.S. residents

Links

$

Enroll in this cycle study!

(U.S. residents only)

dcberne.com/en/menstrual-cycle-study

Contact

Menstrual Cycle Study Team

menstrual.cycle@dcberne.com

More recent projects

Sign up for our newsletter and stay up to date.

* Pflichtfelder
DSGVO *

DCB Research AG

Freiburgstrasse 3
3010 Bern
Switzerland

info@dcberne.com

Impressum

Datenschutzerklärung

The FibreGum study – Changing the course of obesity

The FibreGum study – Changing the course of obesity

by | Apr 3, 2023

Back to Projects

The FibreGum study – Changing the course of obesity

The goal of our study is to increase weight reduction in obese children and adolescents by stimulating the gut microbiome with a chewing-gum containing dietary fibres as an adjunct treatment to standard adiposity therapy.

Non-invasive and low-threshold treatments are needed to combat childhood obesity

Around one in six children in Switzerland is affected by overweight or obesity and the prevalence continues to rise. This increase in obesity and its associated comorbidities represents a huge socio-economic burden, as it leads to increased morbidity and mortality. Obesity is not only a chronic disease in itself, but also a major risk factor for the development of the world’s leading causes of poor health and early death; namely cardiovascular disease, various cancers, diabetes and osteoarthritis.

Preventing obesity in children and adolescents offers a unique opportunity to prevent the path to an unhealthy adult life. A low-threshold offer could be the key to success. For this reason, we have developed a chewing gum enriched with dietary fibre, the “FibreGum”, in cooperation with Delica AG. The aim of the FibreGum is to improve microbial diversity and promote beneficial metabolites while reducing snacking. To investigate the efficacy of this chewing gum, we are conducting a randomised placebo-controlled clinical trial with a cohort of 105 obese children and adolescents. Obese children and adolescents (age 10-16 years, >97th percentile) who would like to participate in the FibreGum study are welcome to ask their family doctor for a referral to the Adipositassprechstunde at the Kinderklinik Bern (http://www.kinderklinik.insel.ch/de/unser-angebot/adipositas/). All participants in the FibreGum study must attend the Adipositassprechstunde.

Project team: Prof. Dr. Maria Luisa Balmer, Inselspital (University Hospital of Bern) and University of Bern (leading the project); Dr. Christoph Saner, Children’s hospital, Inselspital (University Hospital of Bern); Dr. Marco Janner, Children’s hospital, Inselspital (University Hospital of Bern); Prof. Dominik Meinel, University of Applied Sciences and Arts Northwestern Switzerland; Dr. Alexandra Stähli, Zahnmedizinische Kliniken Bern (University of Bern); Valentina Huwiler, Inselspital (University Hospital of Bern) and University of Basel; Marie-Aline Gerard, Diabetes Center Berne

Project funding: Diabetes Center Berne (research project), Von Tobel Stiftung (research project), Walter Fuchs Stiftung (research project), Swiss National Science Foundation

Prof. Dr. Maria Luisa Balmer is the head of the project.

More recent projects

Sign up for our newsletter and stay up to date.

* Pflichtfelder
DSGVO *

DCB Research AG

Freiburgstrasse 3
3010 Bern
Switzerland

info@dcberne.com

Impressum

Datenschutzerklärung

SmartStart Health: Unlocking life​-​changing benefits of CGM in diabetes

SmartStart Health: Unlocking life​-​changing benefits of CGM in diabetes

by | Jan 11, 2023

Back to Projects

SmartStart Health: Unlocking life​-​changing benefits of CGM in diabetes

DCB and SmartStart Health collaborate to develop and validate a world-first patient education mobile app to increase knowledge and improve outcomes among people with diabetes using continuous glucose monitoring (CGM).

Overwhelming amount of CGM data

When people with diabetes/caregivers start using CGM to gain tighter diabetes control, they face a steep learning curve, regardless of how many years they have lived with diabetes. They’re overwhelmed by hundreds of data points per day, trend arrows and fine-tuning settings for alerts and alarms. They are aware that CGM can be a powerful tool for minimising high and low blood glucose levels and improving their quality of life, but they aren’t sure how to achieve these outcomes. Without timely support to use CGM effectively, people with diabetes/caregivers may see CGM data as clear documentation of diabetes management challenges they feel they cannot overcome.

SmartStart CGM as an innovative solution for CGM education

Education is important for people using CGM to be able to understand and use CGM data to make appropriate treatment decisions that lead to quality of life benefits as well as improvements in diabetes outcomes. SmartStart Health is rising to the challenge of CGM-specific patient education with SmartStart CGM, a user-friendly smartphone app. Supported by DCB, diabetes centres in the US and Switzerland will evaluate the new scalable solution in a proof-of-concept study. The partnership aims to analyse the results in Q3 2022 and publish by mid-2023.

The SmartStart CGM app is designed to inform and empower users with interactive micro-learning based on real-world scenarios that reflect the reality of living with diabetes. A telehealth portal for healthcare professionals will enable clinicians to assess patient engagement with the programme.

Project team: Melissa Holloway (Founder & CEO), Kieron Heath (Operations), Effra Digital (Technology consultant), Will Hargreaves (Business development), Jamie Welsh (Content development)

Funding: DCB supports SmartStart Health with 100k CHF funding

Melissa Holloway, CEO and Founder of SmartStart Health

Links

$

SmartStart Health website

smartstart.health

More recent projects

Sign up for our newsletter and stay up to date.

* Pflichtfelder
DSGVO *

DCB Research AG

Freiburgstrasse 3
3010 Bern
Switzerland

info@dcberne.com

Impressum

Datenschutzerklärung